Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
BEIJING, Feb. 08, 2016 -- BeiGene, Ltd. (“BeiGene” or “the Company”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced the closing of its initial public offering of 7,590,000 American Depositary Shares (“ADSs”), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS, before underwriting discounts. This includes the full exercise of the underwriters’ option to purchase additional ADSs. All of the ADSs in the offering were offered by BeiGene. The ADSs are listed on The NASDAQ Global Select Market under the ticker symbol “BGNE.”
Goldman, Sachs & Co., Morgan Stanley, and Cowen and Company acted as joint book-running managers. Baird acted as co-manager of the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 2, 2016. The offering was made only by means of a prospectus, copies of which may be obtained for free from the offices of Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 [email protected]
